UBS Raises Numbers on CVS Caremark (CVS); Comments From Conference Call
Tweet Send to a FriendGet Alerts CVS Hot Sheet
Price: $58.70 -1.36%
Rating Summary:
11 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Rating Summary:
11 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Trade CVS Now!
UBS maintains a 'Buy' on CVS Caremark (NYSE: CVS) price target raised from $49 to $53.
Analyst, Steven Valiquette, said, "It remains quite interesting to us the extent to which the mgmt of CVS is trying to keep investor expectations in check in relation to upside from the Walgreen (NYSE: WAG) / Express Scripts (Nasdaq: ESRX) impasse, but our sense is a growing portion of this former WAG customer base is now likely more inclined to stay with CVS such that we raise our 2013 EPS estimate from $3.70 to $3.75 to reflect an extended retail benefit from the impasse." (UBS raises FY12 EPS estimate from $3.26 to $3.33)
"Shares of CVS appear poised to move higher near-term if there is no WAG/ESRX resolution. We believe there may be resolution over the next month or two, which could cause a temporary dip in CVS."
For an analyst ratings summary and ratings history on CVS Caremark click here. For more ratings news on CVS Caremark click here.
Shares of CVS Caremark closed at $45.92 yesterday, with a 52 week range of $31.30-$46.12.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Steven Valiquette, said, "It remains quite interesting to us the extent to which the mgmt of CVS is trying to keep investor expectations in check in relation to upside from the Walgreen (NYSE: WAG) / Express Scripts (Nasdaq: ESRX) impasse, but our sense is a growing portion of this former WAG customer base is now likely more inclined to stay with CVS such that we raise our 2013 EPS estimate from $3.70 to $3.75 to reflect an extended retail benefit from the impasse." (UBS raises FY12 EPS estimate from $3.26 to $3.33)
"Shares of CVS appear poised to move higher near-term if there is no WAG/ESRX resolution. We believe there may be resolution over the next month or two, which could cause a temporary dip in CVS."
For an analyst ratings summary and ratings history on CVS Caremark click here. For more ratings news on CVS Caremark click here.
Shares of CVS Caremark closed at $45.92 yesterday, with a 52 week range of $31.30-$46.12.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- NetApp (NTAP) Post Solid Q4, Numbers Bumped - Needham & Company
- Wedbush Expects Positive Results from Insmed (INSM) ARIKAC Trial
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
UBS
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
